Literature DB >> 27741350

Measuring cancer evolution from the genome.

Trevor A Graham1, Andrea Sottoriva2.   

Abstract

The temporal dynamics of cancer evolution remain elusive, because it is impractical to longitudinally observe cancers unperturbed by treatment. Consequently, our knowledge of how cancers grow largely derives from inferences made from a single point in time - the endpoint in the cancer's evolution, when it is removed from the body and studied in the laboratory. Fortuitously however, the cancer genome, by virtue of ongoing mutations that uniquely mark clonal lineages within the tumour, provides a rich, yet surreptitious, record of cancer development. In this review, we describe how a cancer's genome can be analysed to reveal the temporal history of mutation and selection, and discuss why both selective and neutral evolution feature prominently in carcinogenesis. We argue that selection in cancer can only be properly studied once we have some understanding of what the absence of selection looks like. We review the data describing punctuated evolution in cancer, and reason that punctuated phenotype evolution is consistent with both gradual and punctuated genome evolution. We conclude that, to map and predict evolutionary trajectories during carcinogenesis, it is critical to better understand the relationship between genotype change and phenotype change.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  clonal evolution of cancer; gradualism; hopeful monsters; intratumour heterogeneity; neutral evolution; next-generation sequencing; punctuated equilibrium; saltation; selection; subclones

Mesh:

Year:  2016        PMID: 27741350     DOI: 10.1002/path.4821

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  26 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

Review 2.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

3.  Detecting repeated cancer evolution from multi-region tumor sequencing data.

Authors:  Giulio Caravagna; Ylenia Giarratano; Daniele Ramazzotti; Ian Tomlinson; Trevor A Graham; Guido Sanguinetti; Andrea Sottoriva
Journal:  Nat Methods       Date:  2018-08-31       Impact factor: 28.547

Review 4.  Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.

Authors:  Mohammad Mijanur Rahman; Trygve O Tollefsbol
Journal:  Methods       Date:  2020-04-18       Impact factor: 3.608

Review 5.  Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.

Authors:  Melissa Schmidt; Richard J Hackett; Ann-Marie Baker; Stuart A C McDonald; Michael Quante; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-02       Impact factor: 46.802

6.  A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.

Authors:  Hongchen Cai; Su Kit Chew; Chuan Li; Min K Tsai; Laura Andrejka; Christopher W Murray; Nicholas W Hughes; Emily G Shuldiner; Emily L Ashkin; Rui Tang; King L Hung; Leo C Chen; Shi Ya C Lee; Maryam Yousefi; Wen-Yang Lin; Christian A Kunder; Le Cong; Christopher D McFarland; Dmitri A Petrov; Charles Swanton; Monte M Winslow
Journal:  Cancer Discov       Date:  2021-02-19       Impact factor: 38.272

7.  Inferring modes of evolution from colorectal cancer with residual polyp of origin.

Authors:  Minsoo Kim; Brooke R Druliner; Nikolaos Vasmatzis; Taejeong Bae; Nicholas Chia; Alexej Abyzov; Lisa A Boardman
Journal:  Oncotarget       Date:  2017-12-26

Review 8.  Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis.

Authors:  Ravi Raj Pal; Vasundhara Rajpal; Priya Singh; Shubhini A Saraf
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

9.  Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors.

Authors:  Ignacio Varela; Pablo Menendez; Alejandra Sanjuan-Pla
Journal:  Oncotarget       Date:  2017-08-16

10.  Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Authors:  Mariangela Russo; Simona Lamba; Annalisa Lorenzato; Alberto Sogari; Giorgio Corti; Giuseppe Rospo; Benedetta Mussolin; Monica Montone; Luca Lazzari; Sabrina Arena; Daniele Oddo; Michael Linnebacher; Andrea Sartore-Bianchi; Filippo Pietrantonio; Salvatore Siena; Federica Di Nicolantonio; Alberto Bardelli
Journal:  Nat Commun       Date:  2018-06-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.